In the hospitalized cohort, we did not observe any impact of CLL treatment status history or impact of potential agents (anti-CD20 antibodies, BTKi and venetoclax), although some studies suggest the protective role of BTK inhibitors or increased severity during venetoclax therapy [11,13,28,29]. This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.